Share of Clicks for top 10 US Pharma & Biotech Neuroscience brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| vraylar.com | 28.79 |
| rexulti.com | 15.44 |
| caplyta.com | 12.53 |
| vraylarhcp.com | 9.71 |
| nurtec.com | 5.06 |
| vyepti.com | 3.64 |
| rexultihcp.com | 3.2 |
| fanapt.com | 2.39 |
| caplytahcp.com | 2.09 |
| wakix.com | 1.47 |
| others | 15.68 |
- vraylar.com - 28.79%
- rexulti.com - 15.44%
- caplyta.com - 12.53%
- vraylarhcp.com - 9.71%
- nurtec.com - 5.06%
- vyepti.com - 3.64%
- rexultihcp.com - 3.2%
- fanapt.com - 2.39%
- caplytahcp.com - 2.09%
- wakix.com - 1.47%
- others - 15.68%
Copyright © Adthena. All rights reserved.
In the competitive landscape of Google PPC, vraylar.com dominates with a 28.79% click share. Following are rexulti.com at 15.44% and caplyta.com at 12.53%. Notably, ‘others’ collectively hold 15.68%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Neuroscience brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | vraylar.com | caplyta.com | nurtec.com | rexulti.com | vraylarhcp.com | vyepti.com | wakix.com | fanapt.com | caplytahcp.com | rexultihcp.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025/12/01 | 32.13% | 16.96% | 2.4% | 11.07% | 14.25% | 2.09% | 0.67% | 0.02% | 1.6% | 1.9% |
| 2025/12/02 | 44.12% | 20.02% | 5.31% | 1.2% | 9.1% | 1.25% | 1.96% | 0.03% | 2.05% | 1.17% |
| 2025/12/03 | 44.61% | 15.01% | 1.78% | 6.39% | 15.51% | 1.81% | 1.61% | 0.01% | 0.82% | 1.66% |
| 2025/12/04 | 55.78% | 6.44% | 3.95% | 3.63% | 10.3% | 2.49% | 2.6% | 0.01% | 0.99% | 0.51% |
| 2025/12/05 | 46.72% | 10.57% | 3.29% | 2.72% | 18.91% | 3.32% | 2.12% | 0.01% | 1.92% | 0.81% |
| 2025/12/06 | 47.72% | 8.05% | 4.02% | 4.54% | 14.75% | 3.5% | 1.45% | 0% | 2.38% | 1.82% |
| 2025/12/07 | 38.77% | 13.73% | 3.57% | 4.24% | 17.81% | 1.79% | 1.62% | 0% | 2.62% | 0.72% |
| 2025/12/08 | 42.49% | 13.89% | 2.71% | 3.22% | 14.68% | 3.2% | 1.55% | 0.87% | 0.69% | 1.23% |
| 2025/12/09 | 44.42% | 11.55% | 2.78% | 2.42% | 16.97% | 1.82% | 1.88% | 1.31% | 2.52% | 1.97% |
| 2025/12/10 | 44.8% | 11.65% | 2.4% | 5.84% | 17.23% | 2.37% | 1.3% | 1.13% | 2.55% | 1.77% |
| 2025/12/11 | 33.46% | 15.13% | 5.38% | 9.4% | 8.5% | 3.04% | 2.21% | 2.65% | 3.86% | 2.22% |
| 2025/12/12 | 46.48% | 3.25% | 4.29% | 4.16% | 16.19% | 3.78% | 1.9% | 2.64% | 1.04% | 2.04% |
| 2025/12/13 | 41.02% | 5.41% | 3.59% | 6.27% | 8.41% | 2.82% | 1.93% | 1.93% | 3.51% | 2.04% |
| 2025/12/14 | 9.46% | 11.35% | 10.45% | 13.76% | 4.78% | 6.65% | 4.1% | 6.69% | 3.85% | 2.22% |
| 2025/12/15 | 9.81% | 20.48% | 6.85% | 15.67% | 2.54% | 3.53% | 2.68% | 4.25% | 0.49% | 4.89% |
| 2025/12/16 | 41.67% | 9.67% | 2.38% | 4.13% | 20.84% | 1.87% | 1.07% | 1.37% | 2.07% | 0.96% |
| 2025/12/17 | 37.5% | 14.34% | 2.38% | 2.1% | 18.84% | 2.16% | 1.42% | 1.63% | 2.78% | 1.05% |
| 2025/12/18 | 38.95% | 16.81% | 1.87% | 3.31% | 15.97% | 2.32% | 1.47% | 1.04% | 1.88% | 0.57% |
| 2025/12/19 | 39.67% | 13.45% | 3.55% | 4.35% | 17.19% | 2.69% | 0.99% | 1.32% | 2.94% | 2.11% |
| 2025/12/20 | 40.67% | 8.74% | 5.18% | 4.15% | 15.53% | 3.22% | 1.68% | 1.4% | 2.81% | 1.89% |
| 2025/12/21 | 28.73% | 18.41% | 2.51% | 7.47% | 16.23% | 3.29% | 1.26% | 0.87% | 2.16% | 2.85% |
| 2025/12/22 | 35% | 11.96% | 3.42% | 6.18% | 17.4% | 3.45% | 1.29% | 1.2% | 1.8% | 2.69% |
| 2025/12/23 | 34% | 18.61% | 2.84% | 6.98% | 14.46% | 2.7% | 1.05% | 1.04% | 3.88% | 2.26% |
| 2025/12/24 | 38.96% | 19.8% | 3.11% | 8.04% | 12.48% | 2.71% | 1.67% | 1.33% | 0.94% | 2.14% |
| 2025/12/25 | 45.98% | 10.82% | 1% | 3.22% | 17.72% | 2.82% | 0.88% | 1.46% | 0.92% | 0.62% |
| 2025/12/26 | 41.04% | 17.56% | 2.04% | 4.09% | 14.28% | 2.96% | 1.76% | 1.72% | 1.25% | 2.36% |
| 2025/12/27 | 41.27% | 13.89% | 1.6% | 5.53% | 15.29% | 2.33% | 0.81% | 1.44% | 3.62% | 1.91% |
| 2025/12/28 | 41.95% | 12.96% | 2.27% | 6.42% | 12.62% | 1.95% | 1.31% | 1.8% | 1.35% | 2.19% |
| 2025/12/29 | 29.9% | 19.27% | 3.66% | 10.98% | 9.41% | 3.01% | 2.52% | 0.8% | 2.01% | 3.59% |
| 2025/12/30 | 40.5% | 19.55% | 3.01% | 6.67% | 11.21% | 1.41% | 1.79% | 1.1% | 1.36% | 2.47% |
| 2025/12/31 | 50.15% | 20.94% | 4.96% | 3.96% | 3.14% | 2.37% | 2.35% | 1% | 0.02% | 0.02% |
- vraylar.com
- caplyta.com
- nurtec.com
- rexulti.com
- vraylarhcp.com
- vyepti.com
- wakix.com
- fanapt.com
- caplytahcp.com
- rexultihcp.com
Copyright © Adthena. All rights reserved.
Vraylar.com led December’s PPC spend, peaking at 55.78 on the 4th. Caplyta.com followed, ending strong at 20.94. Nurtec.com and Rexulti.com showed moderate fluctuations, while Vraylarhcp.com and others maintained lower spend levels.
Competitor Count for US Pharma & Biotech Neuroscience
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2025/12/01 | 89 |
| 2025/12/02 | 83 |
| 2025/12/03 | 96 |
| 2025/12/04 | 97 |
| 2025/12/05 | 104 |
| 2025/12/06 | 111 |
| 2025/12/07 | 107 |
| 2025/12/08 | 105 |
| 2025/12/09 | 102 |
| 2025/12/10 | 107 |
| 2025/12/11 | 105 |
| 2025/12/12 | 108 |
| 2025/12/13 | 84 |
| 2025/12/14 | 90 |
| 2025/12/15 | 88 |
| 2025/12/16 | 96 |
| 2025/12/17 | 87 |
| 2025/12/18 | 93 |
| 2025/12/19 | 84 |
| 2025/12/20 | 92 |
| 2025/12/21 | 87 |
| 2025/12/22 | 99 |
| 2025/12/23 | 98 |
| 2025/12/24 | 95 |
| 2025/12/25 | 95 |
| 2025/12/26 | 88 |
| 2025/12/27 | 90 |
| 2025/12/28 | 90 |
| 2025/12/29 | 91 |
| 2025/12/30 | 88 |
| 2025/12/31 | 88 |
Copyright © Adthena. All rights reserved.
December saw a dynamic shift in distinct advertisers, peaking at 111 on December 6th. The month concluded with a stable count of 88, reflecting a balanced competitive landscape.
